Carcinoma in situ of bladder
ICD-10 D09.0 is a billable code used to indicate a diagnosis of carcinoma in situ of bladder.
Carcinoma in situ (CIS) of the bladder is a non-invasive form of bladder cancer characterized by abnormal cells that have not yet invaded deeper tissues. It is often detected through cystoscopy and biopsy, where the presence of atypical cells is confirmed. Patients with CIS may present with symptoms such as hematuria (blood in urine), urinary frequency, and urgency. The condition is considered a precursor to invasive bladder cancer, necessitating close surveillance and management. Treatment options may include intravesical therapy, such as Bacillus Calmette-Guérin (BCG) therapy, or surgical intervention. Regular follow-up with cystoscopy is crucial to monitor for progression to invasive disease, as the risk of progression is significant, particularly in high-grade cases. The prognosis for patients with CIS can vary based on factors such as tumor grade, response to treatment, and the presence of concurrent bladder lesions.
Detailed pathology reports, treatment plans, and follow-up notes are essential.
Diagnosis of CIS during routine cystoscopy, management of recurrent CIS, and treatment response evaluation.
Urologists must ensure accurate staging and grading of tumors to guide treatment and follow-up.
Comprehensive treatment records, including chemotherapy or immunotherapy details.
Management of patients receiving BCG therapy and monitoring for side effects.
Oncologists should document the rationale for treatment choices and patient responses.
Used for diagnosis of CIS during evaluation of hematuria.
Pathology report confirming CIS and details of the cystoscopy.
Urologists must document the findings and any treatment decisions made during the procedure.
Used for administering BCG therapy for CIS.
Record of treatment administration and patient response.
Oncologists should document the rationale for treatment and any side effects experienced by the patient.
Carcinoma in situ is a non-invasive form of cancer where abnormal cells are present but have not invaded surrounding tissues. Invasive bladder cancer, on the other hand, has penetrated deeper layers of the bladder wall and may spread to other parts of the body.
Patients diagnosed with carcinoma in situ of the bladder typically require cystoscopic surveillance every 3 to 6 months for the first 2 years, then annually if no recurrence is detected.
